Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.30), $0.30 better than the analyst estimate of ($1.60). Revenue for the quarter came in at $220.1 million versus the consensus estimate of $193.18 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.